Skip to menu Skip to content Skip to footer

2011

Conference Publication

Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand

Tate, J., Mollee, P., Caldwell, G., Daly, J., Gillis, D., Jenkins, M., Jovanovich, S., Martin, H., Steele, R., Wienholt, L. and AACB Working Party Standardised Reporting of Protein Electrophoresis (2011). Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand. EuroMedLab Berlin 2011, Berlin, Germany, 15-19 May 2011. Berlin, Germany: Walter De Gruyter. doi: 10.1515/CCLM.2011.527

Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand

2011

Conference Publication

A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S. (2011). A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), San Diego, CA, United States, Dec 10-13, 2011. Washington, DC, United States: American Society of Hematology.

A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

2011

Conference Publication

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

2011

Conference Publication

Analytical aspects of standardised protein electrophoresis and immunofixation reporting

Tate, Jill, for the Working Party on Standardised Reporting of Protein Electrophoresis, Mollee, Peter, Caldwell, Grahame, Daly, James, Gillis, David, Jenkins, Margaret, Jovanovich, Sue, Martin, Helen, Steele, Richard and Wienholt, Louise (2011). Analytical aspects of standardised protein electrophoresis and immunofixation reporting. 35th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology, Sydney, NSW Australia, 4-6 June 2010. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0031-3025(16)33167-1

Analytical aspects of standardised protein electrophoresis and immunofixation reporting

2011

Conference Publication

Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study

Morel-Kopp, MC, Tan, CW, Brighton, T, McRae, S, Tran, H, Mollee, P, Kershaw, G, Joseph, J, Coyle, L and Ward, C (2011). Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study. Unknown, unknown, unknown. HOBOKEN: WILEY-BLACKWELL.

Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study

2010

Conference Publication

Survival and prognostic factors amongst Australian patients with AL amyloidosis

Mollee, P, Tate, J, Morris, K, Wellwood, J, Browne, M, Marlton, P, Bird, R, Mills, AK, Wood, P, Mapp, S and Gill, D (2010). Survival and prognostic factors amongst Australian patients with AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome Italy, Apr 18-21, 2010. LONDON: INFORMA HEALTHCARE.

Survival and prognostic factors amongst Australian patients with AL amyloidosis

2010

Conference Publication

WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation

Gray, James X., McMillen, Lyle, Saal, Russell, Lane, Steven, Bird, Robert, Gill, Devinder, Mollee, Peter and Marlton, Paula (2010). WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation. Royal College of Pathologists of Australasia Pathology Update, Melbourne, VIC Australia, 26-28 February 2010. Oxford, United Kingdom: Elsevier. doi: 10.1097/01268031-201042001-00118

WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation

2010

Conference Publication

Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis

Mollee, P., Tate, J., Weiss, D. and Solomon, A. (2010). Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome, Italy, 18-21, April 2010. London, United Kingdom: Informa Healthcare.

Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis

2009

Conference Publication

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study

Mollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. 51st ASH Annual Meeting, New Orleans, LA United States, 5–8 December 2009. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v114.22.1382.1382

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study

2009

Conference Publication

WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML)

Gray, James X, McMillen, Lyle, Saal, Russell, Lane, Steven, Mollee, Peter, Bird, Robert, Gill, Devinder and Marlton, Paula (2009). WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML). 51st ASH Annual Meeting, New Orleans, LA, 5-8 December 2009. American Society of Hematology. doi: 10.1182/blood.v114.22.2639.2639

WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML)

2009

Conference Publication

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

Mollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. 51st ASH Annual Meeting and Exposition, New Orleans, LA, U.S.A., 5-8 December 2009. Washington, DC, U.S.A.: American Society of Hematology.

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

2009

Conference Publication

Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial

Trappe, Ralf, Choquet, Sylvain, Oertel, Stephan H.K., Leblond, Veronique, Dierickx, Daan, Mollee, Peter, Sender, Monica, Ekman, Tor, Zaucha, Jan Maciej, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Dreyling, Martin H., Duhrsen, Ulrich, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Anagnostopoulos, Ioannis, Raphael, Martine, Dorken, Bernd and Riess, Hanno (2009). Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5 - 8 December 2009. Washington, DC, United States: American Society of Hematology.

Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial

2009

Conference Publication

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)

Gray, J. X., McMillen, L., Saal, R., Lane, S., Mollee, P., Bird, R., Gill, D. and Marlton, P. (2009). WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML). 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5-8 December 2009. Washington, DC, United States: American Society of Hematology.

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)

2008

Conference Publication

Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population

Keane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014

Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population

2008

Conference Publication

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

Gill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.3157.3157

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

2008

Conference Publication

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

Gill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th Annual Meeting of the American- Society-of-Hematology, San Francisco, CA, United States, 6 - 9 December 2008. Washington, DC, United States: American Society of Hematology.

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

2008

Conference Publication

Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations

Tate, J.R., Bazeley, S., Sykes, S. and Mollee, P. (2008). Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations. 60th Annual Meeting of the American Association for Clinical Chemistry, Washington, DC, United States, 27-31 July 2008. Washington, DC, United States: American Association for Clinical Chemistry.

Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations

2007

Conference Publication

JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)

Weston, Helen, Bird, Robert, Griffiths, Vanessa, Jones, Mark, Grimmett, Karen, Saal, Russell, Mills, Anthony K., Gill, Devinder, Marlton, Paula and Mollee, Peter (2007). JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th ASH Annual Meeting, Atlanta, GA United States, 8-11 December 2007. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v110.11.2551.2551

JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)

2007

Conference Publication

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

Mollee, Peter, Hourigan, Matthew, Johnson, David, Jones, Mark, Isbel, Nikki, Hawley, Carmel, Marlton, Paula, Gandhi, Maher, Campbell, Scott and Gill, Devinder (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA USA, 8-11 December 2007. Washington, DC USA: American Society of Hematology.

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

2007

Conference Publication

Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients

Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x

Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients